Zoetis Inc - Ordinary Shares - Class A
ZTS
Market Cap$70.03B
Close$
Earnings Call Q4 2023
February 14, 2024 - AI Summary
Zoetis reported strong full-year 2023 results, with revenue of $8.5 billion and adjusted net income of $2.5 billion.
The company achieved 7% operational revenue growth, driven by steady demand for innovative products in both the companion animal and livestock portfolios.
Key growth drivers included the success of monoclonal antibodies for osteoarthritis pain (Librela and Solensia), the dermatology franchise, and the Simparica Trio parasiticides portfolio.
Exclusive for Stockcircle Pro members
Sign up
$103.70
31.3% downside
Current Fair Value
31.3% downsideOvervalued by 31.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $70.03 Billion |
|---|---|
| Enterprise Value | $74.55 Billion |
| Dividend Yield | $1.9794 (1.29%) |
| Earnings per Share | $5.07 |
| Beta | 1.09 |
| Outstanding Shares | 457,359,433 |
| Avg 30 Day Volume | 3,954,117 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 29.87 |
|---|---|
| PEG | 215.19 |
| Price to Sales | 8.38 |
| Price to Book Ratio | 15.09 |
| Enterprise Value to Revenue | 8.73 |
| Enterprise Value to EBIT | 24.27 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 1.31 |
Revenue Sources
No data
ESG Score
No data
About Zoetis Inc
9,200 employees
CEO: Kristin Peck Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines...